precisionmedicineonline20h
Roche's Tiragolumab, Tecentriq Combo Misses Overall Survival Endpoint in PD-L1 Positive NSCLC Trial
The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.
precisionmedicineonline20h
Eisai to Cover APOE Genotyping as Part of Dementia Research Registry in Japan
Eisai and the National Center of Neurology and Psychiatry in Tokyo will study the link between APOE genotype and safety and efficacy of Leqembi.